This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Related articles in The Oncologist Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peters, W. P. Articles by Baynes, R. D. Search for Related Content PubMed PubMed Citation Articles by Peters, W. P. Articles by Baynes, R. D.

High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer^*

Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute at Wayne State University, Detroit, Michigan, USA

Correspondence: Roy D. Baynes, M.D., Ph.D., Professor of Medicine and Oncology, Director Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute at Wayne State University, 3990 John R, 4 Brush South, Detroit, MI 48201, USA. Telephone: 313-966-7021; Fax: 313-966-7656; e-mail: baynesr{at}karmanos.org

Each year in the USA, 180,000 new cases of breast cancer are diagnosed and about 44,000 women die of the disease. Current primary treatment consists of adjuvant chemotherapy and hormone therapy, and statistics show that combination chemotherapy favorably influences the outcomes in both node-negative and node-positive primary disease. However, a significant number of breast cancer patients succumb to the disease, and nearly every patient diagnosed with metastatic breast cancer will be dead within five years.

High-dose chemotherapy (HDC) and peripheral blood progenitor cell transplantation (PBPCT) are based upon laboratory and clinical observations of the ability to modify growth properties of quiescent and replicating cancer cells. A large number of HDC and PBPCT regimens have been evaluated for treatment of metastatic breast cancer, and recent autologous bone marrow transplantation data indicate that three HDC regimens (CPB, CTCb and cytoxan and thiotepa) predominate. Unfortunately, negative media coverage surrounding and subsequent to the presentation of preliminary findings reported at the May 1999 American Society of Clinical Oncologists, that were not allowed adequate follow-up time for full analysis of treatment results, has had a detrimental effect on the ability to conduct trials in this area.

Several randomized trials have been conducted in both the metastatic and high risk primary disease settings. Thorough analysis of these studies indicates an evaluable improvement in favor of HDC and PBPCT in three of the four randomized studies performed in metastatic breast cancer and two of the four high risk primary studies. Also, initial evaluations found that quality of life appeared comparable in patients receiving either HDC or not. Each randomized trial studied asks a different question and, depending on the intensity of HDC regimen, the intensity and duration of the standard dose chemotherapy control and the schedule of events in relation to induction chemotherapy, the outcomes may be quite variable. Still, certain general trends are indentifiable. HDC alone will not completely cure breast cancer and should be considered as part of an overall therapeutic plan. In some of these studies, significantly longer follow-up is required before definitive analysis can be completed.

Key Words. High-dose chemotherapy • Autologous transplantation • Breast cancer • Metastatic • High-risk primary • Hematopoietic stem cells

Related articles in The Oncologist:

Editor's Note

The Oncologist 2000 5: 17. [Full Text]  

This article has been cited by other articles:

				F Bellati, M Pernice, N Manci, I Palaia, F Tomao, C Marchetti, M. Zullo, L Muzii, R Angioli, and P. B. Panici Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors Ann. Onc., April 1, 2007; 18(4): 722 - 729. [Abstract] [Full Text] [PDF]

				R. C. Leonard, M. Untch, and F. Von Koch Management of anaemia in patients with breast cancer: role of epoetin Ann. Onc., May 1, 2005; 16(5): 817 - 824. [Abstract] [Full Text] [PDF]

				W. P. Peters, G. L. Rosner, J. J. Vredenburgh, E. J. Shpall, M. Crump, P. G. Richardson, M. W. Schuster, L. B. Marks, C. Cirrincione, L. Norton, et al. Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13 J. Clin. Oncol., April 1, 2005; 23(10): 2191 - 2200. [Abstract] [Full Text] [PDF]

				D. Cella, D. Dobrez, and J. Glaspy Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes Ann. Onc., April 1, 2003; 14(4): 511 - 519. [Abstract] [Full Text] [PDF]

				A. Schneeweiss, M. Hensel, P. Sinn, T. Khbeis, R. Haas, G. Bastert, and A. D. Ho Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose Ann. Onc., May 1, 2002; 13(5): 679 - 688. [Abstract] [Full Text] [PDF]

				M. Hensel, G. Egerer, A. Schneeweiss, H. Goldschmidt, and A. D. Ho Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation Ann. Onc., February 20, 2002; 13(2): 209 - 217. [Abstract] [Full Text] [PDF]

				S. Rodenhuis The Status of High-Dose Chemotherapy in Breast Cancer Oncologist, October 1, 2000; 5(5): 369 - 375. [Abstract] [Full Text]

				J. O'Shaughnessy High Dose Chemotherapy for Breast Cancer: Taking Stock Oncologist, February 1, 2000; 5(1): 14 - 17. [Full Text]